Humans live in a 24-hour environment, in which light and darkness follow a diurnal pattern. Our circadian pacemaker, the suprachiasmatic nuclei (SCN) in the hypothalamus, is entrained to the 24-hour solar day via a pathway from the retina and synchronises our internal biological rhythms. Rhythmic variations in ambient illumination impact behaviours such as rest during sleep and activity during wakefulness as well as their underlying biological processes. Rather recently, the availability of artificial light has substantially changed the light environment, especially during evening and night hours. This may increase the risk of developing circadian rhythm sleep–wake disorders (CRSWD), which are often caused by a misalignment of endogenous circadian rhythms and external light–dark cycles. While the exact relationship between the availability of artificial light and CRSWD remains to be established, nocturnal light has been shown to alter circadian rhythms and sleep in humans. On the other hand, light can also be used as an effective and noninvasive therapeutic option with little to no side effects, to improve sleep, mood and general well-being. This article reviews our current state of knowledge regarding the effects of light on circadian rhythms, sleep, and mood.

LED *Shared senior authors. light sources have a discontinuous light spectrum with a prominent ‘blue’ peak between 450 and 470 nm that influences non-image forming responses in humans. We tested an LED lighting solution mimicking a daylight spectrum on visual comfort, circadian physiology, daytime alertness, mood, cognitive performance and sleep. Fifteen young males twice spent 49 hours in the laboratory under a conventional-LED and under a daylight-LED condition in a balanced cross over design flanked by a baseline and a post-light exposure night. Despite different light spectra, the photopic lux and the correlated colour temperature of the lighting were the same for both LEDs. The colour rendering index and the melanopic strength were 25.3% and 21%, respectively, higher for the daylight LED than the conventional LED. The volunteers had better visual comfort, felt more alert and happier in the morning and evening under daylight LED than conventional LED, while the diurnal melatonin profile, psychomotor vigilance and working memory performance were not significantly different. Delta EEG activity (0.75–4.5 Hz) was significantly higher after daylight-LED than conventional-LED exposure during the post-light exposure night. We have evidence that a daylight-LED solution has beneficial effects on visual comfort, daytime alertness, mood and sleep intensity in healthy volunteers.

Objective: Perinatal depression (PND) is a severe complication of pregnancy, affecting both mothers and newborns. Bright light therapy (BLT) has only been tested in a few studies for treating either antenatal or postnatal depression. We conducted a pilot trial to investigate the efficacy and safety of BLT for PND occurring at any time across the perinatal period.Methods: A single‐blind RCT was carried out in women with an EPDS >12 from the 2nd gestational trimester until 9 months postpartum. Participants received either 30‐minutes morning BLT (10′000 lux) or dim red light (DRL, 19 lux) for 6 weeks.Results: Twenty‐two women were randomised to BLT (n = 11) or DRL (n = 11). Among those receiving BLT, 73% achieved remission (improvement ≥50%, EPDS score ≤ 12), in contrast to 27% in the DRL group (p = 0.04). A significant influence of time on EPDS score and group‐time interaction emerged, with a greater reduction in the BLT‐group across the follow‐up period. No women in either group reported major side effects.Conclusion: Morning BLT induced a significant remission from PND as compared to DRL and this effect was maintained across the perinatal period. BLT showed an excellent safety profile and was well‐tolerated, thus representing a valid therapeutic strategy in this vulnerable perinatal population.